trending Market Intelligence /marketintelligence/en/news-insights/trending/ZHA4RAozdNHm4sZrrFdLSA2 content esgSubNav
In This List

US district court rejects Teva patent infringement claims

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


US district court rejects Teva patent infringement claims

The U.S. District Court for the District of Delaware rejected Teva Pharmaceutical Industries Ltd.'s patent infringement claims against the generic versions of its multiple sclerosis drug Copaxone.

The court invalidated all asserted claims against five of the six drug applications for a generic version of Copaxone. Mylan NV and Sandoz Inc. are two of the companies seeking to sell a generic version of Copaxone.

Teva plans to appeal the decision.